Figure 6
From: Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models
The splenic population of CD8+ T cells increases following combination therapy and varies with tumor immunogenicity. Female (M to F) or male (M to M) M3-9-M tumor-bearing mice received three doses of intratumoral HSV1716 injection followed by intraperitoneal injection of anti-PD-1 or control antibody as shown in Fig. 4a. Immune cell infiltrates in spleens were evaluated by flow cytometry analyses 72 hours after last dose of HSV1716 injection. Data show mean and SEM (n = 3~6 per treatment group). Statistical analysis was performed by a one-way ANOVA with Tukey-adjusted post hoc tests (*p < 0.05, **p < 0.01 and ***p < 0.001).
